FM
PETX

Family Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Family Management’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-12,000
Closed -$74K – 73
2017
Q3 		$74K Hold
12,000
– – 0.05% 63
2017
Q2 		$87K Buy
+12,000
New +$73.8K 0.06% 64

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Family Management's PETX Position: Q4 2017 in Review

Family Management sold out of Aratana Therapeutics, Inc. (PETX) in Q4 2017, closing a stake of 12,000 shares — an estimated $74K sold.

Family Management first reported a position in PETX in Q2 2017 and held it in 2 quarters. The position peaked at $87K in Q2 2017. 105 funds tracked by Wall St. Rank hold PETX as of Q4 2017.

  • Family Management reported no remaining Aratana Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Family Management sold 12,000 Aratana Therapeutics, Inc. shares in Q4 2017, an estimated $74K.
  • Family Management first reported a position in Aratana Therapeutics, Inc. in Q2 2017 and held it in 2 quarters.
  • Family Management's Aratana Therapeutics, Inc. position peaked at $87K in Q2 2017.
  • 105 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q4 2017.

Based on Family Management's 13F filing for Q4 2017, filed 15 Feb 2018.